Patents Assigned to Merck Patents GmbH
  • Publication number: 20170226422
    Abstract: The present invention relates to liquid crystal media comprising polymerisable mesogenic compounds with a bent shape, and to electro-optical displays comprising these media as light modulation media. In particular the electro-optical displays according to the present invention are displays, which are operated at a temperature, at which the liquid crystal modulation media are in an optically isotropic phase, preferably in a blue phase.
    Type: Application
    Filed: July 17, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Michael WITTEK, Norihiko TANAKA, Kevin ADLEM, Matthias BREMER, David WILKES, Ming-Chou WU
  • Publication number: 20170226080
    Abstract: Compounds according to Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: July 10, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Timo HEINRICH, Frank ZENKE, Felix ROHDICH, Manja FRIESE-HAMIM, Diane HAHN
  • Publication number: 20170224860
    Abstract: A sample preparation container, preferably for use in sterility testing, comprising a housing (1) having a housing wall (2) defining an inside space (3), a support on which a membrane filter is placed or is to be placed so as to get in contact with a sampling fluid to be introduced into the inside space (3), and at least one inlet opening (4) to the inside space (3) and at least one outlet opening from the inside space (3). A sampling port (5) is provided for allowing access from the outside to the inside space (3), wherein said sampling port (5) is closed by a septum (6) and the septum (6) is separated from the inside space (3) by a barrier wall (7) which is preferably piercable or breakable on application of an external force, preferably applied through a sampling instrument like a needle (8).
    Type: Application
    Filed: September 16, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Gerard MULLER, Mathieu ARRAULT
  • Publication number: 20170226199
    Abstract: The invention relates to anti-TNFa antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFa antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Application
    Filed: June 26, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Ralf GUENTHER, Stefan BECKER, Laura RHIEL, Bjoern HOCK, Christian SCHROETER
  • Publication number: 20170226421
    Abstract: The invention relates to a polymerisable LC medium with negative optical dispersion, a polymer film with negative optical dispersion obtainable from such a medium, and the use of the polymerisable LC medium and polymer film in optical, electro optical, electronic, semiconducting or luminescent components or devices.
    Type: Application
    Filed: July 13, 2015
    Publication date: August 10, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Joseph SARGENT, Owain Llyr PARRI, Kevin ADLEM, Hassan ARASI
  • Patent number: 9725462
    Abstract: Compounds of the formula I in which R, R1 and R2 have the meanings indicated in claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and/or systemic lupus.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Lars Burgdorf, Daniel Kuhn, Tatjana Ross, Carl Deutsch
  • Patent number: 9728724
    Abstract: The present invention relates to a polymer which comprises at least one structural unit which contains at least one aldehyde group, and to a process for the preparation of a crosslinkable or crosslinked polymer including a polymer which contains aldehyde groups. The present invention thus also relates to a crosslinkable polymer and a crosslinked polymer which is prepared by the process according to the invention, and to the use of this crosslinked polymer in electronic devices, in particular in organic electroluminescent devices, so-called OLEDs (OLED=organic light emitting device).
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Aurélie Ludemann, Rémi M. Anémian, Alice Julliart
  • Patent number: 9726933
    Abstract: The present invention relates to liquid-crystalline media (LC media) having negative or positive dielectric anisotropy comprising self-alignment additives (SAMs) with an at least one bifunctional or polyfunctional anchor group, which effects the homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The invention therefore also encompasses LC displays having homeotropic alignment of the liquid-crystalline medium (LC medium) without conventional imide alignment layers. The LC media may be supplemented by a polymerizable or polymerized component, which serves for stabilization of the alignment, for adjustment of the tilt angle and/or as passivation layer.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Graziano Archetti, Andreas Taugerbeck, Renate Bender, Rocco Fortte, Peer Kirsch, Izumi Saito
  • Patent number: 9725446
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
  • Patent number: 9724388
    Abstract: The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administration every 2 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-administration of a anti-inflammatory drug.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 8, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring
  • Publication number: 20170218070
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: January 9, 2017
    Publication date: August 3, 2017
    Applicant: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • Publication number: 20170216213
    Abstract: The present invention relates to directly compressible co-mixtures for the production of tablets having delayed release of active compound which comprise polyvinyl alcohols (PVAs) and microcrystalline celluloses (MCCs).
    Type: Application
    Filed: July 3, 2015
    Publication date: August 3, 2017
    Applicant: Merck Patent GmbH
    Inventors: Roberto OGNIBENE, Finn BAUER, Thorsten WEDEL, Guenter MODDELMOG
  • Publication number: 20170222157
    Abstract: The present invention relates to compounds, compositions and formulations comprising same and to opto-electronic devices comprising the compounds and compositions according to the invention.
    Type: Application
    Filed: June 30, 2015
    Publication date: August 3, 2017
    Applicant: Merck Patent GmbH
    Inventors: Anja Jatsch, Amir Hossain Parham, Thomas Eberle, Tobias Grossmann, Jonas Valentin Kroeber
  • Publication number: 20170217863
    Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.
    Type: Application
    Filed: July 15, 2015
    Publication date: August 3, 2017
    Applicant: MERCK PATENT GmbH
    Inventors: Reiner FRIEDRICH, Gerhard JONSCHKER
  • Patent number: 9718764
    Abstract: The present invention relates to compounds which are suitable as synthesis precursors for the production of electronically active materials for use in organic electroluminescence devices.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: August 1, 2017
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Amir Hossain Parham, Anja Jatsch
  • Patent number: 9719016
    Abstract: Disclosed are a liquid crystal (LC) medium containing a polymerisable compound, a process for its preparation, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in an LC display of the polymer sustained alignment (PSA) type, and to an LC display, especially a PSA display.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 1, 2017
    Assignee: Merck Patent GmbH
    Inventors: Ji-Won Jeong, Hyun-Jin Yoon, Eun-Kyu Lee, Min-Ok Jin, Yong-Kuk Yun
  • Patent number: 9718785
    Abstract: Compounds of the formula I in which R, Y, R1, X1, X2, X3 and q have the meanings indicated in claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 1, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Christos Tsaklakidis, Wolfgang Staehle, Birgitta Leuthner, Thomas Fuchss
  • Patent number: 9718826
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: August 1, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Dieter Dorsch
  • Publication number: 20170209380
    Abstract: The present invention relates to a directly compressible composition for the production of tablets which comprise fine-grained polyvinyl alcohols (PVAs) and fine-grained microcrystalline celluloses (MCCs) in a co-mixture. The present invention also relates to the use of this mixture and to a process for the preparation thereof.
    Type: Application
    Filed: July 3, 2015
    Publication date: July 27, 2017
    Applicant: Merck Patent GmbH
    Inventors: Roberto OGNIBENE, Finn BAUER, Thorsten WEDEL, Guenter MODDELMOG
  • Publication number: 20170210990
    Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Application
    Filed: June 19, 2015
    Publication date: July 27, 2017
    Applicant: Merck Patent GmbH
    Inventors: Kevin ADLEM, Owain Llyr PARRI, Rachel TUFFIN, Hassan ARASI, Benjamin SNOW